A Study of BGM0504 in Chinese Patients With Type 2 Diabetes

NCT06974825 · Completed

Last updated 2026-05-28

This clinical trial tests the effects of BGM0504 in Chinese adults with type 2 diabetes to measure changes in blood sugar levels over time.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 67 people

Who can join Ages 18–65 · all sexes

Timeline Started 2023-08 · est. completion 2024-08

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06974825 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate the efficacy and safety of BGM0504 in Chinese patients with Type 2 Diabetes.

BGM0504 Administered SC Drug

5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.
BGM0504 Administered SC Drug

Experimental: 10 mg BGM0504 10 mg BGM0504 administered SC once a week.
BGM0504 Administered SC Drug

Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.
Semaglutide Administered SC Drug

Active Comparator: 1 mg Semaglutide 1 mg semaglutide administered SC once a week
Placebo Administered SC Drug

Placebo Comparator: Placebo Placebo administered SC once a week.

Main thing measured	Change From Baseline in Hemoglobin A1c (HbA1c)
Sponsor	BrightGene Bio-Medical Technology Co., Ltd.
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06974825 ↗